Table 1.
Comparisons among the Ames assay, traditional alkaline comet assay conditions, and conditions that trap NER intermediates (+ HU + AraC) in a genotoxic screen of nine known in vivo genotoxins (120). Statistical significance is designated as ‘+’ and ‘−’. Dose ranges for statistically significant results are indicated
| Genotoxicity | ||||||
|---|---|---|---|---|---|---|
| Alkaline CometChip HepaRG™ | Alkaline CometChip HepaRG™ (+ HU + AraC) | Carcinogenicity | ||||
| In vivo genotoxins | Ames | +/− | ‘+’ dose range | +/− | ‘+’ dose range | IARC classification (92) |
| Etoposide | + (134) | − | + | 10 μM | Group 1 | |
| 2,4-DAT | + (135) | − | + | 10 mM | Group 2B | |
| CP | + (135) | − | + | 5–10 mM | Group 1 | |
| PCA | + (135) | − | − | Group 2B | ||
| NDMA | + (135) | + | 2.5 - 20 mM | + | 2.5 - 20 mM | Group 2A |
| HQ | − (135) | − | + | 0.33 mM | Group 3 | |
| B[a]P | + (135) | − | + | 5–10 μM | Group 1 | |
| CAM | − (136) | − | + | 3.1 mM | Group 2A | |
| Cisplatin | + (137) | − | − | Group 2A | ||
IARC classification: Group 1: human carcinogen, Group 2A: probably human carcinogen, Group 2B: possible human carcinogen, Group 3: not classifiable as to its carcinogenicity to humans.